Abstract
Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 722-727 |
| Number of pages | 6 |
| Journal | Arteriosclerosis, Thrombosis, and Vascular Biology |
| Volume | 27 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2007 |
| Externally published | Yes |
Keywords
- Anticoagulants
- Coagulation
- Factor IX (fIX), monoclonal antibodies (mAb), RNA aptamers
Fingerprint
Dive into the research topics of 'Factor IXa inhibitors as novel anticoagulants'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver